AUTHOR=Ma Yuxin , Shi Xinhong , Zhao Kun , Hu Shuyi , Shi Yue , Jiang Yingying , Liu Yiling , Lu Lin , Chang Yuting , Zhou Fei , Dai Yingying , Wu Zipeng , Li Shiyi , Qian Zhiying , Xu Xia , Li Chenchen , Shen Bo , Zhou Guoren , Chen Cheng , Wang Xiaohua , Feng Jifeng 

TITLE=Optimal response to tislelizumab plus chemotherapy in metastatic triple-negative breast cancer: a case report and literature review

JOURNAL=Frontiers in Oncology

VOLUME=Volume 14 - 2024

YEAR=2024

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1328844

DOI=10.3389/fonc.2024.1328844

ISSN=2234-943X

ABSTRACT=Metastatic triple-negative breast cancer (mTNBC) is one of the worst prognosis breast cancer.Immune checkpoint inhibitors (ICIs) plus chemotherapy gets promising survival benefits. Herein, we report a 51-year-old woman whose metastatic lesions were diagnosed as triple-negative subtype, received tislelizumab plus eribulin treatment and achieved excellent efficacy. To our best knowledge, this study is the first attempt to present tislelizumab in combination with eribulin in mTNBC. New treatments resulting in prolonged survival and durable clinical responses would benefit mTNBC patients and then we summarize the possible influencing factors of the interaction between tislelizumab and eribulin.